FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 321:287-292 August 3, 1989 Number 5 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To evaluate the frequency and the pathogenesis of hyperuricemia and gout during cyclosporine therapy, we studied renal-transplant recipients who were treated with either cyclosporine and prednisone (n = 129) or azathioprine and prednisone (n = 168). Among the patients with stable allograft function and serum creatinine concentrations below 265 mumol per liter, hyperuricemia was more common in the cyclosporine group than in the azathioprine group (84 percent vs. 30 percent; P = 0.0001). Gout developed in nine patients (7 percent) in the cyclosporine group, but no episodes occurred in the azathioprine group. Serum urate levels became elevated in 90 percent of the patients in the cyclosporine group who were treated with diuretics, as compared with 60 percent of those not treated with diuretics (P = 0.001); in the azathioprine group, the corresponding values were 47 percent and 15 percent (P = 0.0001). Serum urate levels did not correlate with trough blood cyclosporine levels in a selected subgroup (n = 40) of patients from the cyclosporine group, who were studied from 4 to 96 weeks after transplantation. Detailed studies of urate metabolism in six cyclosporine-treated patients revealed normal turnover rates for urate and decreases in creatinine and urate clearance, as compared with seven control subjects. We conclude that hyperuricemia is a common complication of cyclosporine therapy and is caused by decreased renal urate clearance. Gouty arthritis is the cause of considerable morbidity among renal-transplant recipients who receive cyclosporine.

Source Information

Human Purine Research Center, University Hospital, Ann Arbor, Mich.

This article has been cited by other articles:

• Pascual, E, Perdiguero, M (2006). Gout, diuretics and the kidney.. Ann Rheum Dis 65: 981-982 [Full Text]  
• Choi, H. K., Mount, D. B., Reginato, A. M. (2005). Pathogenesis of Gout. ANN INTERN MED 143: 499-516 [Full Text]  
• Suresh, E (2005). Diagnosis and management of gout: a rational approach. Postgrad. Med. J. 81: 572-579 [Abstract] [Full Text]  
• Gerster, J C, Dudler, M, Halkic, N, Gillet, M (2004). Gout in liver transplant patients receiving tacrolimus. Ann Rheum Dis 63: 894-895 [Full Text]  
• Perez-Ruiz, F., Gomez-Ullate, P., Amenabar, J. J., Zarraga, S., Calabozo, M., Herrero-Beites, A. M., Nolla, J. M. (2003). Long-term efficacy of hyperuricaemia treatment in renal transplant patients. Nephrol Dial Transplant 18: 603-606 [Abstract] [Full Text]  
• Schmidt, A., Gruber, U., Bohmig, G., Koller, E., Mayer, G. (2001). The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 16: 1034-1037 [Abstract] [Full Text]  
• KASISKE, B. L., VAZQUEZ, M. A., HARMON, W. E., BROWN, R. S., DANOVITCH, G. M., GASTON, R. S., ROTH, D., SCANDLING, J. D. JR., SINGER, G. G. (2000). Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. J. Am. Soc. Nephrol. 11: S1-S86 [Abstract] [Full Text]  
• CLIVE, D. M. (2000). Renal Transplant-Associated Hyperuricemia and Gout. J. Am. Soc. Nephrol. 11: 974-979 [Full Text]  
• Sennesael, J., Lamote, J., Violet, I., Tasse, S., Verbeelen, D. (1995). Comparison of Perindopril and Amlodipine in Cyclosporine-Treated Renal Allograft Recipients. Hypertension 26: 436-444 [Abstract] [Full Text]